Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab and Teclistamab vs Standard Care in High-Risk Relapsed/Refractory Multiple Myeloma
NCT06948084Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2027
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in multiple myeloma (MM), sponsored by National Cancer Institute. Planned start May 2027; status: recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06948084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948084.